Axicabtagene ciloleucel
From Ganfyd
(Redirected from KTE-C19)
rINN: Axicabtagene ciloleucel
Other Names
KTE-C19, axi-cel ®
Pharmacological Information
Web information on Axicabtagene ciloleucel
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Wikipedia on Axicabtagene ciloleucel (Less technical, ? quality control)
References
- ↑ Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine. 2017 Dec; 377(26):2531-2544.(Print-Electronic) (Link to article – subscription may be required.)
- ↑ Kite Pharma, Inc Press release 28 Feb 2017
- ↑ Press release Kite Pharma 8 August 2017